Roger Chapman

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1986927/publications.pdf

Version: 2024-02-01

| | | 279487 | 360668 |
|----------|----------------|--------------|----------------|
| 39 | 7,021 | 23 | 35 |
| papers | citations | h-index | g-index |
| | | | |
| | | | |
| | | | |
| 39 | 39 | 39 | 5815 |
| all docs | docs citations | times ranked | citing authors |
| | | | |

| # | Article | IF | CITATIONS |
|----|--|-----|-----------|
| 1 | International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis. Journal of Hepatology, 1999, 31, 929-938. | 1.8 | 2,681 |
| 2 | Analysis of Successful Immune Responses in Persons Infected with Hepatitis C Virus. Journal of Experimental Medicine, 2000, 191, 1499-1512. | 4.2 | 1,165 |
| 3 | Diagnosis and management of primary sclerosing cholangitis. Hepatology, 2010, 51, 660-678. | 3.6 | 1,048 |
| 4 | A preliminary trial of high-dose ursodeoxycholic acid in primary sclerosing cholangitis. Gastroenterology, 2001, 121, 900-907. | 0.6 | 330 |
| 5 | Type 1 Autoimmune Pancreatitis and IgG4-Related Sclerosing Cholangitis Is Associated With Extrapancreatic Organ Failure, Malignancy, and Mortality in a Prospective UK Cohort. American Journal of Gastroenterology, 2014, 109, 1675-1683. | 0.2 | 210 |
| 6 | A randomized trial of obeticholic acid monotherapy in patients with primary biliary cholangitis. Hepatology, 2018, 67, 1890-1902. | 3.6 | 204 |
| 7 | norUrsodeoxycholic acid improves cholestasis in primary sclerosing cholangitis. Journal of Hepatology, 2017, 67, 549-558. | 1.8 | 202 |
| 8 | Patients with small duct primary sclerosing cholangitis have a favourable long term prognosis. Gut, 2002, 51, 731-735. | 6.1 | 184 |
| 9 | Randomized Clinical Trial: Macrogol/PEG 3350 Plus Electrolytes for Treatment of Patients With Constipation Associated With Irritable Bowel Syndrome. American Journal of Gastroenterology, 2013, 108, 1508-1515. | 0.2 | 133 |
| 10 | Liver transplantation for acute hepatic failure?. Lancet, The, 1990, 335, 32-35. | 6.3 | 92 |
| 11 | Expression of HLA-DR antigens on bile duct epithelium in primary sclerosing cholangitis Gut, 1988, 29, 422-427. | 6.1 | 89 |
| 12 | Etiopathogenesis of primary sclerosing cholangitis. World Journal of Gastroenterology, 2008, 14, 3350. | 1.4 | 77 |
| 13 | Review article: current management of primary sclerosing cholangitis. Alimentary Pharmacology and Therapeutics, 2005, 21, 933-948. | 1.9 | 71 |
| 14 | Risk factors for biliary tract carcinogenesis. Annals of Oncology, 1999, 10 Suppl 4, 308-11. | 0.6 | 67 |
| 15 | Role of Immune Factors in the Pathogenesis of Primary Sclerosing Cholangitis. Seminars in Liver Disease, 1991, 11, 1-4. | 1.8 | 55 |
| 16 | Aetiology and natural history of primary sclerosing cholangitis—a decade of progress?. Gut, 1991, 32, 1433-1435. | 6.1 | 50 |
| 17 | PSC, AIH and overlap syndrome in inflammatory bowel disease. Clinics and Research in Hepatology and Gastroenterology, 2012, 36, 420-436. | 0.7 | 47 |
| 18 | Outcomes after ileal pouch anal anastomosis in patients with primary sclerosing cholangitis. Journal of Crohn's and Colitis, 2014, 8, 662-670. | 0.6 | 45 |

| # | Article | IF | Citations |
|----|---|-----|-----------|
| 19 | New Therapeutic Strategies for Primary Sclerosing Cholangitis. Seminars in Liver Disease, 2016, 36, 005-014. | 1.8 | 41 |
| 20 | Combination Therapy with Interferon-?? and Ribavirin for Hepatitis C. BioDrugs, 2001, 15, 225-238. | 2.2 | 40 |
| 21 | Early primary biliary cholangitis is characterised by brain abnormalities on cerebral magnetic resonance imaging. Alimentary Pharmacology and Therapeutics, 2016, 44, 936-945. | 1.9 | 27 |
| 22 | Detection of antineutrophil cytoplasmic antibodies in primary sclerosing cholangitis: a comparison of the alkaline phosphatase and immunofluorescent techniques. European Journal of Gastroenterology and Hepatology, 1997, 9, 575-580. | 0.8 | 26 |
| 23 | Chemoprevention and screening in primary sclerosing cholangitis. Postgraduate Medical Journal, 2008, 84, 228-237. | 0.9 | 24 |
| 24 | Editorial: further evidence for the role of serum alkaline phosphatase as a useful surrogate marker of prognosis in <scp>PSC</scp> . Alimentary Pharmacology and Therapeutics, 2015, 41, 149-151. | 1.9 | 19 |
| 25 | Raised gamma-glutamyltransferase activity and the need for liver biopsy BMJ: British Medical Journal, 1991, 302, 388-389. | 2.4 | 17 |
| 26 | The colon and PSC: new liver, new danger?. Gut, 1998, 43, 595-596. | 6.1 | 15 |
| 27 | The immunology of primary sclerosing cholangitis. Seminars in Immunopathology, 1990, 12, 121-8. | 4.0 | 13 |
| 28 | Inappropriate expression of blood group antigens in hepatic allografts. Hepatology, 1994, 19, 876-881. | 3.6 | 12 |
| 29 | Bile duct basement membrane thickening in primary sclerosing cholangitis. Histopathology, 2016, 68, 819-824. | 1.6 | 9 |
| 30 | The enigma of anti-neutrophil antibodies in ulcerative colitis primary sclerosing cholangitis: Important genetic marker or epiphenomenon?. Hepatology, 1995, 21, 1473-1474. | 3.6 | 7 |
| 31 | Medical treatment of primary sclerosing cholangitis with ursodeoxycholic acid. Digestive and Liver Disease, 2003, 35, 306-308. | 0.4 | 5 |
| 32 | Mapping chronic liver disease questionnaire scores onto SF-6D utility values in patients with primary sclerosing cholangitis. Quality of Life Research, 2016, 25, 947-957. | 1.5 | 5 |
| 33 | To perform or not to perform liver biopsy-that is the question. Gut, 2002, 51, 9-10. | 6.1 | 4 |
| 34 | Genomeâ€wide association studies in primary sclerosing cholangitis: Still more questions than answers?. Hepatology, 2011, 53, 2133-2135. | 3.6 | 4 |
| 35 | Editorial: vancomycin – a promising option for the treatment of primary sclerosing cholangitis?. Alimentary Pharmacology and Therapeutics, 2018, 47, 1321-1322. | 1.9 | 3 |
| 36 | OP07 Phenotypic description of a large cohort of PSC patients in the UK. Gut, 2011, 60, A53-A53. | 6.1 | 0 |

3

| # | Article | IF | CITATIONS |
|----|---|-----|-----------|
| 37 | Response to Drs Shearer and Ford. American Journal of Gastroenterology, 2014, 109, 136. | 0.2 | O |
| 38 | A rare cause of colonic thickening and lymphadenopathy. Gut, 2017, 66, 78-78. | 6.1 | 0 |
| 39 | Provision and standards of care for treatment and follow-up of patients with auto-immune hepatitis (AIH). Frontline Gastroenterology, 2022, 13, flgastro-2021-101928. | 0.9 | 0 |